Compendium of Cancer Genome Aberrations

Changes

HAEM5:Volunteer Assignments and Opportunities (view source)

Revision as of 20:27, 17 December 2023

652 bytes added ,  20:27, 17 December 2023
no edit summary
Line 2: Line 2:  
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content
 
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content
 
|-
 
|-
−
!Disease (5th Edition)!!Page Type!!Author (5th Edition)!!Date Assigned to Author (5th Edition)!!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review!!Notes (5th Edition)
+
!Disease (5th Edition)!!Page Type!!Author (5th Edition)!!Date Assigned to Author (5th Edition)!!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition)
 
!Correlated Prior Disease Name (4th Edition)
 
!Correlated Prior Disease Name (4th Edition)
 
!Correlated Prior Author (4th Edition)
 
!Correlated Prior Author (4th Edition)
 +
!Date of Last Editor Review (4th Edition)
 
!Notes (4th Edition)
 
!Notes (4th Edition)
 
|-
 
|-
Line 12: Line 13:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 26: Line 28:  
|NEW
 
|NEW
 
|NEW
 
|NEW
 +
|
 
|
 
|
 
|-
 
|-
Line 31: Line 34:  
|NEW
 
|NEW
 
|NEW
 
|NEW
 +
|
 
|
 
|
 
|-
 
|-
Line 36: Line 40:  
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
 
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
 
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 +
|Date page was created
 
|
 
|
 
|-
 
|-
Line 41: Line 46:  
|Chronic Neutrophilic Leukemia (CNL)
 
|Chronic Neutrophilic Leukemia (CNL)
 
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
 
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
 +
|Date page was created
 
|
 
|
 
|-
 
|-
Line 46: Line 52:  
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
 
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
 
|Chelsea D. Kramish; Daynna J.Wolff
 
|Chelsea D. Kramish; Daynna J.Wolff
 +
|
 
|
 
|
 
|-
 
|-
Line 51: Line 58:  
|Polycythemia Vera (PV)
 
|Polycythemia Vera (PV)
 
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
 
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
 +
|
 
|
 
|
 
|-
 
|-
 
|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| ||
 
|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| ||
 
|Essential Thrombocythemia (ET)
 
|Essential Thrombocythemia (ET)
 +
|
 
|
 
|
 
|
 
|
Line 61: Line 70:  
|
 
|
 
|
 
|
 +
|8/4/2020 before submission<br />
 
|
 
|
 
|-
 
|-
Line 67: Line 77:  
|
 
|
 
|
 
|
 +
|PENDING importing content and reference formatting; FQR has emailed SR several times, last 4/20/22
 
|-
 
|-
 
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| ||
 
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 74: Line 86:  
|-
 
|-
 
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| ||
 
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 79: Line 92:  
|-
 
|-
 
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| ||
 
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 84: Line 98:  
|-
 
|-
 
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| ||
 
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 89: Line 104:  
|-
 
|-
 
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 94: Line 110:  
|-
 
|-
 
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 99: Line 116:  
|-
 
|-
 
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 104: Line 122:  
|-
 
|-
 
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 109: Line 128:  
|-
 
|-
 
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 114: Line 134:  
|-
 
|-
 
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 119: Line 140:  
|-
 
|-
 
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 124: Line 146:  
|-
 
|-
 
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 129: Line 152:  
|-
 
|-
 
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
 
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 134: Line 158:  
|-
 
|-
 
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
 
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 139: Line 164:  
|-
 
|-
 
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| ||
 
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 144: Line 170:  
|-
 
|-
 
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia|| || || || ||FQR|| ||
 
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 149: Line 176:  
|-
 
|-
 
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 154: Line 182:  
|-
 
|-
 
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 159: Line 188:  
|-
 
|-
 
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 164: Line 194:  
|-
 
|-
 
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 169: Line 200:  
|-
 
|-
 
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 174: Line 206:  
|-
 
|-
 
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 179: Line 212:  
|-
 
|-
 
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 191: Line 225:  
|
 
|
 
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
 
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
 +
|
 
|
 
|
 
|
 
|
Line 205: Line 240:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 219: Line 255:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 233: Line 270:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 247: Line 285:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 261: Line 300:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 275: Line 315:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 289: Line 330:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 303: Line 345:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 317: Line 360:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 331: Line 375:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 345: Line 390:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 359: Line 405:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 373: Line 420:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 387: Line 435:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 401: Line 450:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 415: Line 465:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 429: Line 480:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 443: Line 495:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 457: Line 510:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 471: Line 525:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 485: Line 540:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 499: Line 555:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 513: Line 570:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 527: Line 585:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 541: Line 600:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 555: Line 615:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 569: Line 630:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 583: Line 645:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 597: Line 660:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 611: Line 675:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 625: Line 690:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 639: Line 705:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 650: Line 717:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 669: Line 737:  
|
 
|
 
|Greg Corboy (GC)
 
|Greg Corboy (GC)
 +
|
 
|
 
|
 
|
 
|
Line 683: Line 752:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 697: Line 767:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 711: Line 782:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 725: Line 797:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 739: Line 812:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 753: Line 827:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 767: Line 842:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 781: Line 857:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 795: Line 872:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 809: Line 887:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 820: Line 899:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 839: Line 919:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 853: Line 934:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 867: Line 949:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 881: Line 964:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 895: Line 979:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 909: Line 994:  
|
 
|
 
|Holli Drendel (HD)
 
|Holli Drendel (HD)
 +
|
 
|
 
|
 
|
 
|
Line 923: Line 1,009:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 937: Line 1,024:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 951: Line 1,039:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 965: Line 1,054:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 979: Line 1,069:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 993: Line 1,084:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,007: Line 1,099:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,021: Line 1,114:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,035: Line 1,129:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,049: Line 1,144:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,063: Line 1,159:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,077: Line 1,174:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,091: Line 1,189:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,099: Line 1,198:  
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
 
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,104: Line 1,204:  
|-
 
|-
 
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG|| ||
 
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,109: Line 1,210:  
|-
 
|-
 
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,114: Line 1,216:  
|-
 
|-
 
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,119: Line 1,222:  
|-
 
|-
 
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,131: Line 1,235:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,145: Line 1,250:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,159: Line 1,265:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,173: Line 1,280:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,187: Line 1,295:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,201: Line 1,310:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,215: Line 1,325:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,229: Line 1,340:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,243: Line 1,355:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,257: Line 1,370:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,271: Line 1,385:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,285: Line 1,400:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,299: Line 1,415:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,313: Line 1,430:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,327: Line 1,445:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,334: Line 1,453:  
|-
 
|-
 
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
 
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,339: Line 1,459:  
|-
 
|-
 
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,344: Line 1,465:  
|-
 
|-
 
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
 
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,349: Line 1,471:  
|-
 
|-
 
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| ||
 
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,354: Line 1,477:  
|-
 
|-
 
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| ||
 
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,359: Line 1,483:  
|-
 
|-
 
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| ||
 
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,364: Line 1,489:  
|-
 
|-
 
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| ||
 
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,369: Line 1,495:  
|-
 
|-
 
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,374: Line 1,501:  
|-
 
|-
 
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| ||
 
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,379: Line 1,507:  
|-
 
|-
 
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,384: Line 1,513:  
|-
 
|-
 
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,389: Line 1,519:  
|-
 
|-
 
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| ||
 
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,394: Line 1,525:  
|-
 
|-
 
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
 
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,399: Line 1,531:  
|-
 
|-
 
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||
 
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,404: Line 1,537:  
|-
 
|-
 
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
 
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,409: Line 1,543:  
|-
 
|-
 
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,414: Line 1,549:  
|-
 
|-
 
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||
 
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,419: Line 1,555:  
|-
 
|-
 
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| ||
 
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,424: Line 1,561:  
|-
 
|-
 
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| ||
 
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,429: Line 1,567:  
|-
 
|-
 
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
 
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,434: Line 1,573:  
|-
 
|-
 
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,439: Line 1,579:  
|-
 
|-
 
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
 
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,444: Line 1,585:  
|-
 
|-
 
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| ||
 
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,449: Line 1,591:  
|-
 
|-
 
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| ||
 
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,454: Line 1,597:  
|-
 
|-
 
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
 
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,459: Line 1,603:  
|-
 
|-
 
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
 
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,464: Line 1,609:  
|-
 
|-
 
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| ||
 
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,469: Line 1,615:  
|-
 
|-
 
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| ||
 
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,474: Line 1,621:  
|-
 
|-
 
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
 
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,486: Line 1,634:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,493: Line 1,642:  
|-
 
|-
 
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
 
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,498: Line 1,648:  
|-
 
|-
 
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
 
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,504: Line 1,655:  
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
 
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,510: Line 1,662:  
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
 
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,516: Line 1,669:  
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
 
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,522: Line 1,676:  
|Mu heavy chain disease||Disease|| || || || || ||SG
 
|Mu heavy chain disease||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,528: Line 1,683:  
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
 
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,534: Line 1,690:  
|Alpha heavy chain disease||Disease|| || || || || ||SG
 
|Alpha heavy chain disease||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,540: Line 1,697:  
|Plasmacytoma||Disease|| || || || || ||SG
 
|Plasmacytoma||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,546: Line 1,704:  
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
 
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,552: Line 1,711:  
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
 
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,561: Line 1,721:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 1,574: Line 1,735:  
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
 
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,579: Line 1,741:  
|-
 
|-
 
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
 
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,584: Line 1,747:  
|-
 
|-
 
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
 
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,589: Line 1,753:  
|-
 
|-
 
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
 
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,601: Line 1,766:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,615: Line 1,781:  
|
 
|
 
|SK
 
|SK
 +
|
 
|
 
|
 
|
 
|
Line 1,622: Line 1,789:  
|-
 
|-
 
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
 
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,627: Line 1,795:  
|-
 
|-
 
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| ||
 
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,632: Line 1,801:  
|-
 
|-
 
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK|| ||
 
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,637: Line 1,807:  
|-
 
|-
 
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| ||
 
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,642: Line 1,813:  
|-
 
|-
 
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
 
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,647: Line 1,819:  
|-
 
|-
 
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,652: Line 1,825:  
|-
 
|-
 
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,657: Line 1,831:  
|-
 
|-
 
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| ||
 
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,662: Line 1,837:  
|-
 
|-
 
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,667: Line 1,843:  
|-
 
|-
 
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
 
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,672: Line 1,849:  
|-
 
|-
 
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,677: Line 1,855:  
|-
 
|-
 
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,682: Line 1,861:  
|-
 
|-
 
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,687: Line 1,867:  
|-
 
|-
 
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,692: Line 1,873:  
|-
 
|-
 
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
 
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,697: Line 1,879:  
|-
 
|-
 
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
 
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,702: Line 1,885:  
|-
 
|-
 
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| ||
 
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,707: Line 1,891:  
|-
 
|-
 
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
 
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,712: Line 1,897:  
|-
 
|-
 
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| ||
 
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,717: Line 1,903:  
|-
 
|-
 
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
 
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,722: Line 1,909:  
|-
 
|-
 
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
 
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,727: Line 1,915:  
|-
 
|-
 
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| ||
 
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,732: Line 1,921:  
|-
 
|-
 
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK|| ||
 
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,737: Line 1,927:  
|-
 
|-
 
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| ||
 
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,742: Line 1,933:  
|-
 
|-
 
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
 
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,747: Line 1,939:  
|-
 
|-
 
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK|| ||
 
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,752: Line 1,945:  
|-
 
|-
 
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,757: Line 1,951:  
|-
 
|-
 
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,762: Line 1,957:  
|-
 
|-
 
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,767: Line 1,963:  
|-
 
|-
 
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
 
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,772: Line 1,969:  
|-
 
|-
 
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,777: Line 1,975:  
|-
 
|-
 
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
 
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,782: Line 1,981:  
|-
 
|-
 
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| ||
 
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,791: Line 1,991:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 1,810: Line 2,011:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,824: Line 2,026:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,838: Line 2,041:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,852: Line 2,056:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,866: Line 2,071:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,880: Line 2,086:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,894: Line 2,101:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,905: Line 2,113:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 1,917: Line 2,126:  
|-
 
|-
 
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
 
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,922: Line 2,132:  
|-
 
|-
 
|Bloom syndrome||Disease|| || || || || ||NA|| ||
 
|Bloom syndrome||Disease|| || || || || ||NA|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,927: Line 2,138:  
|-
 
|-
 
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
 
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,932: Line 2,144:  
|-
 
|-
 
|RASopathies||Disease|| || || || || ||NA|| ||
 
|RASopathies||Disease|| || || || || ||NA|| ||
 +
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|}
 
|}
Retrieved from "https://content.ccga.io/index.php/Special:MobileDiff/13903"